Publications by authors named "Takayuki Shimazaki"
Article Synopsis
- The study aimed to find out which factors might lead to a relapse of rheumatoid arthritis (RA) symptoms when patients reduce their methotrexate (MTX) dose while on a combination therapy with golimumab (GLM).* -
- Researchers analyzed data from 304 RA patients, noting that 16.8% of those who reduced their MTX dosage experienced a relapse; factors such as history of cardiovascular disease, gastrointestinal disease, and liver disease were found to increase the odds of relapse.* -
- The findings suggest that doctors should carefully consider these health histories, along with previous use of non-steroidal anti-inflammatory drugs (NSAIDs), before deciding to reduce MTX doses in RA patients to minimize the risk
Objectives: To evaluate the cost-effectiveness of biologics and methotrexate (MTX) for rheumatoid arthritis (RA) using the number needed to treat (NNT) concept and total actual health care cost.
Methods: This study included 121 RA patients with newly prescribed biologics and/or MTX between 2012 and 2017. The NNT was calculated based on the 24 week remission rate of Disease Activity Score in 28 joints using erythrocyte sedimentation rate (DAS28-ESR) and Clinical Disease Activity Index (CDAI).